EUCTR2014-005263-33-DE进行中（未招募）1 期
Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP
Medizinische Fakultät der Universität Bonn0 个研究点目标入组 15 人开始时间: 2015年2月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- 未提供
研究者
相似试验
尚未招募
3 期
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
已完成
不适用
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
已完成
2 期
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumNCT02537054University Hospital, Bonn15
已完成
不适用
Outcomes of intravitreal aflibercept (Eylea) treatment for treatment-naive contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed intravitreal ranibizumab in the first eyeeovascular age-related macular degenerationJPRN-UMIN000033786Seoul National University Hospital21
进行中（未招募）
不适用
Treatment of a chorioretinal disease characterized by alterations in the elastic lamina of the Bruch's membrane, and which typically manifest themselves as streaks radial departure from the optic nerveEUCTR2014-000986-30-ITIRCCS Ospedale San Raffaele U.O. Oculistica